GAVI facts and figures

in page functions
 

Statistics measuring Gavi, the Vaccine Alliance's impact on global immunisation

Every year, academics, journalists, teachers and students ask for statistics detailing Gavi's results since the Vaccine Alliance was established in 2000. Sourcing the Gavi Secretariat and members of the Vaccine Alliance, including WHO, UNICEF and civil society organisations, these key facts and figures list Gavi's achievements to date as well as demonstrating the Vaccine Alliance's catalytic role within global immunisation.

US$ 80-100 billion in economic benefits

Investing in Gavi’s 2016-2020 strategy has the potential to deliver US$ 80-100 billion in costs averted related to illness, such as productivity loss due to death/disability, treatment costs, caretaker productivity loss and transport costs.

Source: Stack M et al. Estimated economic benefits during Decade of Vaccines, Health Affairs 2011

+215 million

By the end of 2014, 15 countries in the African meningitis belt had collectively immunised more than 215 million people against meningitis A with support from Gavi.

Source: WHO 2014

+73

Gavi support is available to the 73 poorest countries in the world. Over 20 countries are projected to graduate from Gavi’s support by 2020.

Source: Gavi

1 in 5

In total, 1 in 5 children in Gavi-supported countries are still missing out on the basic package of childhood vaccines. 95% of children do not yet have access to all 11 vaccines recommended by WHO for infants in all countries.

Source: WHO/UNICEF 2015

70%

One woman dies from cervical cancer every two minutes - or 266,000 a year- over 85% in the developing world. 70% of cervical cancer cases can be prevented with HPV vaccine.

Source: WHO

7 million

Since its launch in 2000, Gavi has helped developing countries to prevent 7 million future deaths from hepatitis B, Haemophilus influenzae type b (Hib), measles, meningitis A, pneumococcal disease, rotavirus diarrhoea and yellow fever.

Source: Gavi / Bill & Melinda Gates Foundation

500 million

Since 2000, Gavi support has contributed to the immunisation of an additional 500 million children.

Source: WHO/UNICEF

47 million

By the end of 2014, Vaccine Alliance support had contributed to immunising 47 million children against pneumococcal disease. Gavi surpassed its 2015 target of 45 introductions more than 1 year ahead of schedule.

Source: WHO/UNICEF 2015

+243,000,000

Gavi support will assist countries to immunise a further 243 million children between 2011 and 2015.

Source: Gavi

26%

Pneumonia and diarrhoea account for 26% of deaths in under-fives in Gavi-supported countries.

Source: CHERG-WHO 2014

73 countries

Gavi support is available to the 73 poorest countries in the world. By the end of 2013, 22 countries were projected to graduate from Gavi’s support by 2020.

Source: Gavi

US$ 9.9 billion

The total commitments as of 30 June 2015 are US$ 9.9 billion. This includes current commitments from year 2000 up to 2020 for both country programmes and investment cases.

Source: Gavi

3.9 million

The Vaccine Alliance’s support for vaccines will contribute to averting an estimated 3.9 million future deaths between 2011 and 2015.

Source: Gavi

+40%

The weighted average price of pentavalent vaccine per dose has dropped from US$ 3.56 in 2003 to US$ 1.90 in 2014.

Source: Gavi

1.5 million

In 2012, approximately 6.6 million children died before the age of five. WHO estimates that 1.5 million of these deaths are due to vaccine-preventable diseases.

Source: WHO

5 -> 16

From 5 to 16 vaccine manufacturers supplying Gavi – from 1 to 10 based in emerging markets.

2001: 5 vaccine manufacturers - 1 based in an emerging market;
2014: 16 vaccine manufacturers– 10 based in emerging markets.

Source: Gavi

19 million

Nearly 19 million infants remain unimmunised in the world each year.

Source: WHO/UNICEF 2015

close icon

modal window here